Osaka, Japan, June 24, 2020 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new assignment of Directors. The details are as follows;
Name |
Category |
Role |
|
Christophe Weber |
Internal |
Existing |
Representative Director, |
Masato Iwasaki |
Internal |
Existing |
Director, President, Japan Pharma Business Unit |
Andrew Plump |
Internal |
Existing |
Director, President, Research & Development |
Constantine Saroukos |
Internal |
Existing |
Director, Chief Financial Officer |
Masahiro Sakane |
External |
Existing |
External Director, Chair of the Board Meeting |
Olivier Bohuon |
External |
Existing |
External Director |
Jean-Luc Butel |
External |
Existing |
External Director |
Ian Clark |
External |
Existing |
External Director |
Yoshiaki Fujimori |
External |
Existing |
External Director |
Steven Gillis |
External |
Existing |
External Director |
Shiro Kuniya |
External |
Existing |
External Director |
Toshiyuki Shiga |
External |
Existing |
External Director |
Name |
Category |
Role |
|
Yasuhiko Yamanaka |
Internal |
Existing |
Director, Full-time Audit & Supervisory Committee member |
Koji Hatsukawa |
External |
Existing |
External Director, Chairperson of Audit & Supervisory Committee |
Emiko Higashi |
External |
Existing |
External Director, Audit & Supervisory Committee member |
Michel Orsinger |
External |
Existing |
External Director, Audit & Supervisory Committee member |
Media Contact:
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095